PRPaul Joseph Rozance

Paul Joseph Rozance

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul Joseph Rozance has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Elevated catecholamine derivatives homovanillic acid and vanillylmandelic acid in the plasma and amniotic fluid of growth-restricted fetal sheep

    by Ahmed Moutwakil, Alicia White, Stephanie R. Wesolowski, Laura D. Brown, Paul J. Rozance

    Fetal growth restriction (FGR) caused by placental insufficiency is characterized by fetal hypoxemia and elevated catecholamines. We hypothesized that the catecholamine metabolites homovanillic acid (HVA) and vanillylmandelic acid (VMA) would be elevated in a sheep model of placental insufficiency and FGR. We measured HVA and VMA in fetal arterial plasma and amniotic fluid and analyzed their relationships with fetal weight, sex, and concentrations of fetal arterial norepinephrine (NE), oxygen, insulin, and IGF-1. Compared to controls, FGR fetuses had higher arterial plasma concentrations of HVA (39%), VMA (53%), and NE (369%), and lower arterial blood oxygen (26%) and plasma insulin (62%) and IGF-1 (59%). Fetal arterial HVA and VMA were positively correlated with NE and inversely correlated with fetal oxygen and IGF-1 concentrations and fetal weight. Amniotic fluid concentrations of HVA and VMA were also elevated in FGR fetuses. These findings support HVA and VMA as biochemical markers of chronically elevated fetal catecholamine concentrations, with potential utility for identifying fetuses with chronic hypoxemia. The presence of these metabolites in amniotic fluid also suggests the feasibility of non-invasive assessment at the time of or shortly after birth. This manuscript identifies homovanillic acid (HVA) and vanillylmandelic acid (VMA) as biochemical markers of chronic fetal hypoxemia in a sheep model of FGR and are elevated in both plasma and amniotic fluid of FGR fetuses. These data demonstrate strong correlations between HVA/VMA and fetal NE, oxygen content, IGF-1, and fetal weight. This work supports future studies assessing HVA/VMA as potential non-invasive biomarkers in amniotic fluid sampled at delivery to improve newborn risk stratification beyond size-based criteria.

  • Experimental chronic fetal hyperglucagonemia stimulates hepatic pathways for amino acid catabolism and gluconeogenesis

    by Amelia R Tanner, Sarah N Cilvik, Marjorie A Nguyen, Laura D Brown, Russell V Anthony, Clyde J Wright, Stephanie R Wesolowski, Paul J Rozance

    Glucagon activates amino acid catabolism and gluconeogenesis in adults. Elevated glucagon concentrations in the fetus occur in pregnancy complications, such as fetal growth restriction (FGR) and hypoxia, yet the impact of chronic fetal hyperglucagonemia is unknown. Using chronically catheterized pregnant sheep, glucose tracers, and liver tissue biopsies, we investigated the effects of nine days of glucagon infusion at 5 or 50 ng/kg/min in late-gestation fetal sheep that increased plasma glucagon concentrations by 800%. Glucagon-infused fetuses were euglycemic and exhibited lower plasma and hepatic amino acid concentrations. They also had increased hepatic mRNA expression of amino acid catabolism genes, including ARG2, GLS2, BCAT1, BCAT2, GLUL, HAL, UROC1, and PPARGC1A. Metabolite profiling in liver tissue revealed enrichment of pathways associated with amino acid degradation, elevated tri- and diphosphate nucleotides, and changes in fatty acid metabolites, supporting enhanced hepatic energy metabolism from amino acid oxidation. Hepatic glycogen content was reduced in glucagon-infused fetuses and the gluconeogenic genes PCK1 and G6PC1 were increased, although fetal glucose production was not detected. These findings demonstrate that in the fetal liver, chronic hyperglucagonemia activates amino acid catabolic pathways, indicating a physiological role for glucagon in regulating fetal amino acid homeostasis. These findings have implications for understanding fetal hepatic adaptations during chronic fetal hyperglucagonemia that can occur in the setting of FGR or hypoxia.

  • Slow-twitch oxidative myofiber proportions and capillary number per myofiber are reduced in growth-restricted fetal sheep

    by Tristan B. Dear, Eileen I. Chang, Saif I. Al-Juboori, Jane Stremming, Stephanie R. Wesolowski, Sonnet S. Jonker, Paul J. Rozance, Evgenia Dobrinskikh, Laura D. Brown

    Pregnancies affected by placental insufficiency-induced FGR result in fewer slow-twitch oxidative myofibers and lower capillary number per myofiber in fetal skeletal muscle by late gestation.


  • Open Access

    A Two-Hour Fetal Glucagon Infusion Stimulates Hepatic Catabolism of Amino Acids in Fetal Sheep

    by Amelia R. Tanner, Sarah N. Cilvik, Marjorie A. Nguyen, Evgenia Dobrinskikh, Russell V. Anthony, Stephanie R. Wesolowski, Paul J. Rozance

    Postnatally, glucagon acutely lowers plasma amino acid (AA) concentrations by stimulating hepatic AA catabolism, but its fetal actions remain unclear. This study tested whether a 2 h fetal glucagon infusion would stimulate hepatic AA catabolism and inhibit placental AA transfer. Late-gestation pregnant sheep (0.9 gestation) underwent surgical, vascular catheterization and received fetal glucagon (n = 8) or vehicle infusions (n = 8) in a crossover design with a 48 h washout period. Nutrient uptake and utilization were assessed during each infusion, and fetal liver and placental tissue were collected post-infusion under hyperglucagonemic (n = 4) or vehicle (n = 4) conditions. Glucagon receptor was identified in fetal hepatocyte and trophoblast cells. Glucagon reduced fetal plasma AA concentrations by 20% (p = 0.0103) and increased plasma glucose by 47% (p = 0.0152), leading to a three-fold rise in fetal plasma insulin (p = 0.0459). Hepatic gene expression associated with AA catabolism and gluconeogenesis increased (p < 0.0500) following glucagon infusion, and hepatic metabolomic analysis showed enrichment in AA metabolism pathways. However, placental AA transfer was unaffected by 2 h fetal glucagon infusions. In conclusion, a 2 h glucagon infusion stimulates hepatic glucose production and enhances AA catabolism in the fetal liver, lowering plasma AA concentrations. The primary acute effects of fetal glucagon are hepatic, as placental AA transfer is unchanged.


  • Open Access

    IGF-1 LR3 does not promote growth in late-gestation growth-restricted fetal sheep

    by Alicia White, Jane Stremming, Stephanie R. Wesolowski, Saif I. Al-Juboori, Evgenia Dobrinskikh, Sean W. Limesand, Laura D. Brown, Paul J. Rozance

    IGF-1 LR3 treatment administered directly into growth-restricted fetal sheep circulation did not improve fetal growth or attenuate circulating insulin or fetal GSIS. Importantly, IGF-1 LR3 treatment reduced circulating amino acids, notably branched-chain amino acids, which have been shown to potentiate GSIS and protein accretion supporting fetal growth.


  • Chronic late gestation fetal hyperglucagonaemia results in lower insulin secretion, pancreatic mass, islet area and beta‐ and α‐cell proliferation

    by Sarah N. Cilvik, Brit Boehmer, Stephanie R. Wesolowski, Laura D. Brown, Paul J. Rozance

    Fetal glucagon concentrations are elevated in the presence of a compromised intrauterine environment, as in cases of placental insufficiency and perinatal acidaemia. Our objective was to investigate the impact of late gestation fetal hyperglucagonaemia on in vivo insulin secretion and pancreatic islet structure. Chronically catheterized late gestation fetal sheep received an intravenous infusion of glucagon at low (5 ng/kg/min; GCG‐5) or high (50 ng/kg/min; GCG‐50) concentrations or a vehicle control (CON) for 8–10 days. Glucose‐stimulated fetal insulin secretion (GSIS) was measured following 3 h (acute response) and 8–10 days (chronic response) of experimental infusions. Insulin, glucose and amino acid concentrations were measured longitudinally. The pancreas was collected at the study end for histology and gene expression analysis. Acute exposure (3 h) to GCG‐50 induced a 3‐fold increase in basal insulin concentrations with greater GSIS. Meanwhile, chronic exposure to both GCG‐5 and GCG‐50 decreased basal insulin concentrations 2‐fold by day 8–10. Chronic GCG‐50 also blunted GSIS at the study end. Fetal amino acid concentrations were decreased within 24 h of GCG‐5 and GCG‐50, while there were no differences in fetal glucose. Histologically, GCG‐5 and GCG‐50 had lower β‐ and α‐cell proliferation, as well as lower α‐cell mass and pancreas weight, while GCG‐50 had lower islet area. This study demonstrates that chronic glucagon elevation in late gestation fetuses impairs β‐cell proliferation and insulin secretion, which has the potential to contribute to later‐life diabetes risk. We speculate that the action of glucagon in lower circulating fetal amino acid concentrations may have a suppressive effect on insulin secretion. image Key points: We have previously demonstrated in a chronically catheterized fetal sheep model that experimentally elevated glucagon in the fetus impairs placental function, reduces fetal protein accretion and lowers fetal weight. In the present study, we further characterized the effects of elevated fetal glucagon on fetal physiology with a focus on pancreatic development and β‐cell function. We show that experimentally elevated fetal glucagon results in lower β‐ and α‐cell proliferation, as well as decreased insulin secretion after 8−10 days of glucagon infusion. These results have important implications for β‐cell reserve and later‐life predisposition to diabetes.


  • Mitochondrial respiration is lower in the intrauterine growth‐restricted fetal sheep heart

    by Eileen I. Chang, Jane Stremming, Leslie A. Knaub, Stephanie R. Wesolowski, Paul J. Rozance, Carmen C. Sucharov, Jane E. B. Reusch, Laura D. Brown

    Fetuses affected by intrauterine growth restriction have an increased risk of developing heart disease and failure in adulthood. Compared with controls, late gestation intrauterine growth‐restricted (IUGR) fetal sheep have fewer binucleated cardiomyocytes, reflecting a more immature heart, which may reduce mitochondrial capacity to oxidize substrates. We hypothesized that the late gestation IUGR fetal heart has a lower capacity for mitochondrial oxidative phosphorylation. Left (LV) and right (RV) ventricles from IUGR and control (CON) fetal sheep at 90% gestation were harvested. Mitochondrial respiration (states 1–3, LeakOmy, and maximal respiration) in response to carbohydrates and lipids, citrate synthase (CS) activity, protein expression levels of mitochondrial oxidative phosphorylation complexes (CI–CV), and mRNA expression levels of mitochondrial biosynthesis regulators were measured. The carbohydrate and lipid state 3 respiration rates were lower in IUGR than CON, and CS activity was lower in IUGR LV than CON LV. However, relative CII and CV protein levels were higher in IUGR than CON; CV expression level was higher in IUGR than CON. Genes involved in lipid metabolism had lower expression in IUGR than CON. In addition, the LV and RV demonstrated distinct differences in oxygen flux and gene expression levels, which were independent from CON and IUGR status. Low mitochondrial respiration and CS activity in the IUGR heart compared with CON are consistent with delayed cardiomyocyte maturation, and CII and CV protein expression levels may be upregulated to support ATP production. These insights will provide a better understanding of fetal heart development in an adverse in utero environment. image Key points: Growth‐restricted fetuses have a higher risk of developing and dying from cardiovascular diseases in adulthood. Mitochondria are the main supplier of energy for the heart. As the heart matures, the substrate preference of the mitochondria switches from carbohydrates to lipids. We used a sheep model of intrauterine growth restriction to study the capacity of the mitochondria in the heart to produce energy using either carbohydrate or lipid substrates by measuring how much oxygen was consumed. Our data show that the mitochondria respiration levels in the growth‐restricted fetal heart were lower than in the normally growing fetuses, and the expression levels of genes involved in lipid metabolism were also lower. Differences between the right and left ventricles that are independent of the fetal growth restriction condition were identified. These results indicate an impaired metabolic maturation of the growth‐restricted fetal heart associated with a decreased capacity to oxidize lipids postnatally.


  • Increasing maternal glucose concentrations is insufficient to restore placental glucose transfer in chorionic somatomammotropin RNA interference pregnancies

    by Amelia R. Tanner, Victoria C. Kennedy, Cameron S. Lynch, Quinton A. Winger, Russell V. Anthony, Paul J. Rozance

    The current study demonstrated a novel, critical autocrine role for chorionic somatomammotropin in augmenting placental glucose transfer and maintaining placental oxidative metabolism. In pregnancies with CSH deficiency, excess glucose in maternal circulation is insufficient to overcome fetal hypoglycemia due to impaired placental glucose transfer and elevated placental metabolic demands. This suggests that perturbations in glucose transfer in CSH RNAi pregnancies are due to compromised metabolic efficiency along with reduced placental mass.


  • Open Access

    Fetal Hypoglycemia Induced by Placental SLC2A3-RNA Interference Alters Fetal Pancreas Development and Transcriptome at Mid-Gestation

    by Victoria C. Kennedy, Cameron S. Lynch, Amelia R. Tanner, Quinton A. Winger, Ahmed Gad, Paul J. Rozance, Russell V. Anthony

    Glucose, the primary energy substrate for fetal oxidative processes and growth, is transferred from maternal to fetal circulation down a concentration gradient by placental facilitative glucose transporters. In sheep, SLC2A1 and SLC2A3 are the primary transporters available in the placental epithelium, with SLC2A3 located on the maternal-facing apical trophoblast membrane and SLC2A1 located on the fetal-facing basolateral trophoblast membrane. We have previously reported that impaired placental SLC2A3 glucose transport resulted in smaller, hypoglycemic fetuses with reduced umbilical artery insulin and glucagon concentrations, in addition to diminished pancreas weights. These findings led us to subject RNA derived from SLC2A3-RNAi (RNA interference) and NTS-RNAi (non-targeting sequence) fetal pancreases to qPCR followed by transcriptomic analysis. We identified a total of 771 differentially expressed genes (DEGs). Upregulated pathways were associated with fat digestion and absorption, particularly fatty acid transport, lipid metabolism, and cholesterol biosynthesis, suggesting a potential switch in energetic substrates due to hypoglycemia. Pathways related to molecular transport and cell signaling in addition to pathways influencing growth and metabolism of the developing pancreas were also impacted. A few genes directly related to gluconeogenesis were also differentially expressed. Our results suggest that fetal hypoglycemia during the first half of gestation impacts fetal pancreas development and function that is not limited to β cell activity.


  • Open Access

    Increased hepatic glucose production with lower oxidative metabolism in the growth-restricted fetus

    by Laura D. Brown, Paul J. Rozance, Dong Wang, Evren C. Eroglu, Randall B. Wilkening, Ashley Solmonson, Stephanie R. Wesolowski

    Fetal growth restriction (FGR) is accompanied by early activation of hepatic glucose production (HGP), a hallmark of type 2 diabetes (T2D). Here, we used fetal hepatic catheterization to directly measure HGP and substrate flux in a sheep FGR model. We hypothesized that FGR fetuses would have increased hepatic lactate and amino acid uptake to support increased HGP. Indeed, FGR fetuses compared with normal (CON) fetuses had increased HGP and activation of gluconeogenic genes. Unexpectedly, hepatic pyruvate output was increased, while hepatic lactate and gluconeogenic amino acid uptake rates were decreased in FGR liver. Hepatic oxygen consumption and total substrate uptake rates were lower. In FGR liver tissue, metabolite abundance, 13 C-metabolite labeling, enzymatic activity, and gene expression supported decreased pyruvate oxidation and increased lactate production. Isolated hepatocytes from FGR fetuses had greater intrinsic capacity for lactate-fueled glucose production. FGR livers also had lower energy (ATP) and redox state (NADH/NAD+ ratio). Thus, reduced hepatic oxidative metabolism may make carbons available for increased HGP, but also produces nutrient and energetic stress in FGR liver. Intrinsic programming of these pathways regulating HGP in the FGR fetus may underlie increased HGP and T2D risk postnatally.